US9346798, 215

ID: ALA3950353

Chembl Id: CHEMBL3950353

PubChem CID: 71711979

Max Phase: Preclinical

Molecular Formula: C19H12F4N4O3S2

Molecular Weight: 484.46

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  N#Cc1cc(C(F)(F)F)ccc1N1CCOc2cc(S(=O)(=O)Nc3nccs3)c(F)cc21

Standard InChI:  InChI=1S/C19H12F4N4O3S2/c20-13-8-15-16(9-17(13)32(28,29)26-18-25-3-6-31-18)30-5-4-27(15)14-2-1-12(19(21,22)23)7-11(14)10-24/h1-3,6-9H,4-5H2,(H,25,26)

Standard InChI Key:  YYWBVRDWEWYDOV-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA3950353

   4-(2-cyano-4-(trifluoromethyl)phenyl)-6-fluoro-N-(thiazol-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-sulfonamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 484.46

Molecular Weight (Monoisotopic): 484.0287

AlogP: 4.50

#Rotatable Bonds: 4

Polar Surface Area: 95.32

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 6.52

CX Basic pKa: 0.59

CX LogP: 4.02

CX LogD: 3.35

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.55

Np Likeness Score: -2.27

References

1.  (2016)  Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors, 

2. La DS, Peterson EA, Bode C, Boezio AA, Bregman H, Chu-Moyer MY, Coats J, DiMauro EF, Dineen TA, Du B, Gao H, Graceffa R, Gunaydin H, Guzman-Perez A, Fremeau R, Huang X, Ilch C, Kornecook TJ, Kreiman C, Ligutti J, Jasmine Lin MH, McDermott JS, Marx I, Matson DJ, McDonough SI, Moyer BD, Nho Nguyen H, Taborn K, Yu V, Weiss MM..  (2017)  The discovery of benzoxazine sulfonamide inhibitors of NaV1.7: Tools that bridge efficacy and target engagement.,  27  (15): [PMID:28629594] [10.1016/j.bmcl.2017.05.070]

Source

Source(2):

• Scientific Literature
• BindingDB Database